OTTAWA, ONTARIO--(Marketwire - July 19, 2011) - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF)("PharmaGap" or "the Company") today announced that it has completed contractual arrangements and program design for model development and testing of its lead cancer drug GAP-107B8 using human bladder cancer in rats with ITR Laboratories Canada Inc. (ITR) of Baie d'Urfe Quebec.